Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework
International Journal of Nanomedicine · 2026-11 · Volume 21 · 1-30
DOI: 10.2147/ijn.s653639 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-11. Verfasst von Haodong He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department and Institute of Urology, Hubei Provincial Clinical Research Center for Minimally Invasive Treatment of Urology, Tongji Hospital, Tongji M…. Hauptthemen laut MEDLINE: Nanomedicine, Receptors, Chimeric Antigen, Cell Engineering, Immunotherapy, Adoptive. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Nanomedicine is enabling in vivo chimeric antigen receptor (CAR) engineering of myeloid cells, but exposure and uptake do not establish a functional CAR-macrophage product. This oncology-focused narrative review organizes the evidence along five stages: anatomical access, cellular uptake, productive intracellular availability, CAR-protein expression, and antigen-dependent function. Cell identity and state are a cross-stage validation dimension rather than a sixth sequential event. Human tumor-associated macrophage atlases motivate measuring which cells express CAR, while an all-human acute myeloid leukemia screen challenges a universal CD47-centered phagocytosis hierarchy. Neither establishes a universally preferred solid-tumor macrophage state or checkpoint. We distinguish murine and human preclinical studies, peer-reviewed patient data, conference reports, sponsor disclosures, and trial registrations. Early in vivo myeloid programs support technical feasibility and repeat dosing, whereas clinically meaningful efficacy and state-selective engineering remain insufficiently established in the selected evidence. Protein-first assays, endpoint-matched models, quantitative cellular pharmacology, and product-specific potency testing offer a practical validation framework, with no validated universal thresholds. The literature cutoff is 31 August 2026. Clinical web information was checked through 12 August 2026.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Institute of Urology, Hubei Provincial Clinical Research Center for Minimally Invasive Treatment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,…
ORCID-Profile: Haodong He, Zhihua Wang, Qidong Xia
Zitieren
APA
He, H., Sun, J., Xu, J., Abudureyimu, M., Yang, Y., Huang, Y., Wang, Z., & Xia, Q. (2026). Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework. International Journal of Nanomedicine, Volume 21, 1-30. https://doi.org/10.2147/ijn.s653639
Vancouver
He H, Sun J, Xu J, Abudureyimu M, Yang Y, Huang Y, et al. Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework. International Journal of Nanomedicine. 2026;Volume 21:1-30. doi:10.2147/ijn.s653639
BibTeX
@article{He2026,
author = {He, Haodong and Sun, Jianxuan and Xu, Jingyu and Abudureyimu, Maimaiti and Yang, Yuxuan and Huang, Yifan and Wang, Zhihua and Xia, Qidong},
title = {Nanomedicine-Enabled in vivo CAR-Macrophage Engineering: Human Evidence, Translational Bottlenecks, and a Validation Framework},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--30},
doi = {10.2147/ijn.s653639}
}
EUVIMED